Log in
Enquire now
‌

US Patent 10150797 Respiratory syncytial virus (RSV) vaccine

Patent 10150797 was granted and assigned to CureVac on December, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
CureVac
CureVac
Current Assignee
CureVac
CureVac
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10150797
Patent Inventor Names
Benjamin Petsch0
Margit Schnee0
Thomas Kramps0
Daniel Voss0
Date of Patent
December 11, 2018
Patent Application Number
15488815
Date Filed
April 17, 2017
Patent Citations Received
‌
US Patent 12109275 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein
0
‌
US Patent 11760992 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
‌
US Patent 11761009 Artificial nucleic acid molecules for improved protein expression
‌
US Patent 11786590 Rotavirus vaccines
‌
US Patent 11834651 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
0
‌
US Patent 11865084 MERS coronavirus vaccine
0
‌
US Patent 11965000 Respiratory syncytial virus (RSV) vaccine
0
‌
US Patent 12083190 Rabies vaccine
0
...
Patent Primary Examiner
‌
Janet L. Andres
Patent abstract

The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10150797 Respiratory syncytial virus (RSV) vaccine

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us